Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group ; volume:13 ; number:1 ; day:11 ; month:10 ; year:2013 ; pages:1-6 ; date:12.2013
BMC cancer ; 13, Heft 1 (11.10.2013), 1-6, 12.2013
- Beteiligte Personen und Organisationen
-
Emile, Jean-François
Tisserand, Julie
Bergougnoux, Loic
Nowak, Frédérique
Faucher, Gladwys
Surel, Sylvie
Lamy, Aude
Lecorre, Delphine
Helias-Rodzewicz, Zofia
Hofman, Paul
Sabourin, Jean-Christophe
Laurent-Puig, Pierre
SpringerLink (Online service)
- DOI
-
10.1186/1471-2407-13-472
- URN
-
urn:nbn:de:1111-201603047597
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:24 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Emile, Jean-François
- Tisserand, Julie
- Bergougnoux, Loic
- Nowak, Frédérique
- Faucher, Gladwys
- Surel, Sylvie
- Lamy, Aude
- Lecorre, Delphine
- Helias-Rodzewicz, Zofia
- Hofman, Paul
- Sabourin, Jean-Christophe
- Laurent-Puig, Pierre
- SpringerLink (Online service)
Ähnliche Objekte (12)
Variations of BRAF mutant allele percentage in melanomas
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
BRAF fusions identified in melanomas have variable treatment responses and phenotypes
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
Braf, Albin
Brautpaar Braf
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy
Variations of BRAF mutant allele percentage in melanomas
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
BRAF fusions identified in melanomas have variable treatment responses and phenotypes
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
Braf, Albin
Brautpaar Braf
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas
BRAF activation by metabolic stress promotes glycolysis sensitizing NRAS Q61 -mutated melanomas to targeted therapy
Variations of BRAF mutant allele percentage in melanomas
Targeted Therapy for Melanomas Without BRAF V600 Mutations
Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
BRAF fusions identified in melanomas have variable treatment responses and phenotypes
Safety and efficacy of vemurafenib in BRAF V600E mutation-positive metastatic melanomas
Braf, Albin
Brautpaar Braf
NRAS Q61R , BRAF V600E immunohistochemistry: a concomitant tool for mutation screening in melanomas
Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing
SRC-RAC1 signaling drives drug resistance to BRAF inhibition in de-differentiated cutaneous melanomas
Activating PIK3CA mutations coexist with BRAF or NRAS mutations in a limited fraction of melanomas